| Budget Amount *help |
¥14,170,000 (Direct Cost: ¥10,900,000、Indirect Cost: ¥3,270,000)
Fiscal Year 2011: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2010: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2009: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2008: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
|
|---|
| Research Abstract |
ITD-Flt3 mutations in AML are associated with extremely poor prognosis of the patients, indicating additional therapeutic strategies are warranted. In the present study, we identified that Survivin positively regulates progression of acute leukemia induced by ITD-Flt3 in mice model. While the data suggest that targeting Survivin can be a novel treatment strategy for ITD-Flt3+acute leukemia, we also found that antagonizing Survivin impairs normal hematopoietic stem cell(HSC) function. However, our data demonstrated that Evi-1 partially but significantly compensates impaired HSC function induced by loss of Survivin, suggesting that manipulation of Survivin/Evi-1 pathway may represent potential salvage strategy to protect HSC in the patients undergoing anti-Survivin therapies.
|
